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T'h is  thesis  descr ibes cxper inrenta l  data of  bradykin in and i ts  re lat ion rv i th
thc ef fects of  angiotensin convcr t ing enzyme inhib i tors.  Thc angiotensin
convert ing enzyme not  only  act ivates angiotensin.  a potent  I r re\sor  substance,
but  a lso inerct ivatcs brac lyk in in,  one of  the most  potent  depressor  substances
known. Al though i t  has been known s ince 1970 that  the angiotensin-
convert ing enzyme, both i ic t ivates angiotensin ancl  i r . ract i " 'a tes bradykin in.  thc
role of bradykinin has always been controversial. In this thesis first the
histor ica l  perspect ive wzrs g iven.  expla in ing why wc were in terested in
bradykrn in in  the f i rs t  p lace (chapter  1) .  In  chapter  2 the controversy between
bradykin in and angiotensin was out l ined.  Angiotensin was prescnted as a
substtrnce primarily aimed at prcservation of the perfusion pressure in the
kidney and hence at  k idney funct ion.  Bradykin in on the other  hand was
presented as a substance aimed predominantly at preservation of the cardiac
funct ion,  especia l ly  at  the local .  t issue level .
The following chapter (3) dealt with the effects of bradykinin and ACE
inhib i tors on ischemia and reper fus ion of  the myocardium. I t  was shown that
bradykinin is present in the effluent of isolated rat hearts; durin-q ischcmia and
reperfus ion bradykin in product ion is  e levated.  Our own data,  in  appendix D,
show that especierl ly during reperfusion bradykinin efflur was elevated and
that  captopr i l  t reatn. rcnt  enhanced th is  phenornenon.  Our rcsul ts  corroborate
those found in vitro and in vivo by other authors: during ischemia and
reperfus ion in  c logs and man,  bradykin in concentrat ions werL 'e levated.
Furthermore, it was shown in isolated rat heerrts that bradykinin has beneficiai
effects on the post-ischemic, reperfused myocardium. Although bradykinin in
the closed chest pig model of ischemia and reperfusion, which we Llse, did not
reduce catecholamine or purirre cfflux from the heart, nor the increase tn
oxygen requirement, it cl id reduce the enzymatic infarct size, as was presented
in appendix J . ' I 'he in  v i t ro ef fects of  bradykin in,  could be enhanced by ACE
inhibitors. Furthermore, it was described thatACE inhibitors thernselves, also
have beneficial effects in ischemia zrnd reperfusion.These effects could in part
be related to braclykinin, and were probably the result of inhibit ion of the local
converting enzyme in the heart. In our pig model early reperfusion is beneficial
in itself as was shown in appendix H, but a considerable improvement was
found after oral pretreatment with zofenopril. In appendix I, the data found
after zofenopril pretreatment showed that not only neurohumoral
deterioration in the acute phase was reduced, but zrlso that electrophysiologic
stabil ity after two weeks was increased. Therapy with converting enzyme
inhibitors post myocardial infarction results in a modulation of the so-called
remodeling process. Remodeling is the process which after myocardial
infarction results in a dilatation of the left ventricle and hence a reduced left
ventricular function. Finally, the first study on therapy with an ACE inhibitor
dur ing ear ly  repcr fns ion in  pat ients wi th a myocardia l  in farct ion,  receiv ing
conconritant thrornbolytic (rcperfusion) thcrapy was discussed. From these
results it can be concluded that ACE inhibitors have beneficial effects on
ischemia followed by reperfusion in man.
The f<lr.rrth chapter dealt with bradykinin and the coronilry circulation. It
was shown that bradykinin as well asACE inhibitors increased coronary flow
in vitro in the isolated rat heart. First cxperimental data in the isolatecl rat
heart, focused on the effects on the coronary flou,were shown. Our data
showcd that bradvkinin incrcrr:,, 'c oronary flotv by stimulating bradykinin-2
receptors and that bradykinin- I re ceptors counteract this effect (Appendix A).
Expcrimental evidence, found in vitro, led to the conclusion that ACE
inhibitors differ rcmarkably in their bradykinin dependency. This was shown
by our  data in  appendix B:  us ing a select ive bradykin in-2 receptor  antug()n is t
we were able to antagonise the vasodilating effects of bradykinin and
enalaprilat almost completely. The vasodilzrting effect of zofenoprilat was only
partly antzrgonized. whereas the vasodilating effects of captopril and its
inactive stereoisomer SR-captopril were not affected itt all. Using
indomethacin the possible involvement of prostaglandins was investigated
(appendix C). It was shown that bradykinin was able to stimulate prostacyclin
production but only in high concer.ttrations; enalaprilat, captopril,
zofenoprilat, or SR-captopril were inactive in this respect. Inhibit ion of this
prostacyclin production did not reduce bradykinins vasodilating capacity in the
isolatecl rat heart. Neither was the vasocli lation of enalaprilzrt. captopril.
zofenoprilat or SR-captopril affected by indornethacin. The bradykinin
induced release of the endothelium derived relaxing factor (EDRF) probably
is a major mechanism involved in this vascldilation. Apart from differences in
bradykinin dependency, ACE inhibitors also differ in their effects that are
unrelated to inhibit ion of the converting enzyme. The potent endogenous
vasodilator EDRF, which has been shown to be nitric oxide (NO), requires
sulfhydryl groups to become active. From this point of vieq it is interesting
that the sulfhydryl group containingACE inhibitors, captopril and zofenopril,
were found to be more potent coronary vasodilators in the isolated rat heart
than the ACE inhibitors lacking such grou1.l. In vivo experiments regarding the
bradykinin dependency of ACE inhibitors were conducted in rats. These data
were presented in appendix E showing that the blood pressure lowering effect
of enalaprilat was to a greater extent bradykinin dependent than that of
zofenoprilat. ln appendix Four data on brzrdykinin dependency of enalaprilat
and zofenoprilat on their regional hemodynamic effects were presented. From
these data it could be concluded that in many organs both enalaprilat and
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zofenopr i la t  reduce vascular  res is tance v ia a bradykin in dcpendent
mechanism, a lbei t  the la t ter  to  a lesser  extent .  This  may bc an inc l icat ion that
the sulfhvdryl group is responsible for direct vasodilating effects in vivo.
Final ly ,  a  c l in ica l  s tudy could hc conducted.  ln  th is  s tudy we d id not  just
investigate the effects of ACE inhibitors on coronary florv or resistzrnce. but we
were interested in the effects on coronary vasoconstriction induced by
sympathetic activation. We found that in patients with coronary lesions that
activation of the sympathetic nervous system. as is achieved with the cold
pressor test and even more with the so- called diving test, causes an increase rn
coronary vascular resistance. This increase in coronary resistartce could be
reduced with captopril. It wzrs argued that the underlying mechanism may of
course be on the one hand,  the wel l  known dimin ished noradrenergic
facil i tation due to lower angiotensin II concentraticlns, but on the other hand
the role of bradykinin in nc'rradrencrgic transmission may be considerecl as
we l l .
In clrapter 5 some wicler thoughts were given to evolving clinical inclications
and possible future developments. The place of ACE inhibitors in the therapy
of ischemic heart disease seems promising. Firstly, therapy with an ACE
inhibitor during the acute phase of early reperfusion after an infarction has
been shown to have beneficial effects in many experimental models. In
patients the first results on ACE, inhibitor therapy during reperfusion, i.e.
during thrombolytic therapy, showed similar results. Of course, these effects
have to be confirmed by larger studies first, before this therapy is used on a
wider scale. Secondly, the prevention of deterioration of the left ventricular
function with ACE inhibitors is an important therapeutic tool against
developing heart failure in patients after a myocardial infarction. Finally, the
use of ACE inhibitors in anginal patients opens two new perspectives.The first
is related to the presence of a sulfhydryl group; it has been shown in vitro that
captopril can reverse nitrate tolerance. and the first clinical data are promising.
The second is related to the interaction ofACE inhibitors with the sympathetic
nervous system. It was shown that captopril reduces the noradrenergic
transmission in the coronary arteries of patients with angina pectoris. It may be
concluded that the mechanism of action of converting enzyme inhibitors on
the coronary flow as well as on ischemia and reperfusion is multifactorial.
Apart from lower angiotensin II concentrations, converting enzyme inhibit ion
resuits in higher bradykinin concentrations. Both factors may contribute
independently to the improvement of a variety of conditions, that have
myocardial ischemia as a common denominator. To the activity of both,
additional phenomena (less noradrenaline release, prostacyclin or EDRF
stimulation, concomitant presence of a sulfhydryl gror.rp; Figure 7) may
contribute. In this thesis, the role of the second, hitherto rather neglected
factor, i.e. bradvkinin is presented more in detail, with special reference fo its
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Figure TThc cardiovascular act ions of thc convert ing enzyme and i ts peptides. An ACE-
inhibitor can reduce angiotensin II  formation and increase bradykinin concentrat ions.
Some ACE-inhibitors can exert an addit ional effect through a sulfhydryl group. SH:
sulthydryl group; EDRF: endothel ium derived relaxing factor; pG: prostaglancl ins.
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